RNAi biotech Arrowhead Pharmaceuticals has sold off more than 7.6 million shares at just under $6 a pop, raising $45 million toward its R&D projects--…

There may be a slightly wider crack in the biotech IPO window this summer as Protagonist Therapeutics announces a larger-than-expected offering.

Cleave Biosciences aims to create novel small molecules that work to control protein homeostasis in order to treat blood and solid cancers. Now, oncology giant…

The value of Neil Woodford’s Patient Capital Trust fell 10.8% as Circassia’s late-phase flop and the ongoing decline of Northwest Biotherapeutics hit home.

Life science VC firms have stumped up $25 million in a Series A raise for Cambridge, MA-based biotech Avrobio as it looks to take its gene therapy work into…

Bioniz Therapeutics is slated to start a Phase I trial for one of its cytokine inhibitors in partnership with the National Institutes of Health (NIH). Now, it’…

Almost all of the biotech IPOs that have priced since the first quarter have broken issue, meaning that they are now trading below their offer price

Specialty pharma InnoPharma was acquired by Pfizer a few years ago for up to $360 million. Now, the team behind that effort is at it again with another…